Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
Authors
Keywords
-
Journal
BMC Cardiovascular Disorders
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-05
DOI
10.1186/s12872-020-01549-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies
- (2018) Fuling Yu et al. ANGIOLOGY
- The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents
- (2018) Xing-An Wu et al. CLINICA CHIMICA ACTA
- Visfatin as marker of isolated coronary artery ectasia and its severity
- (2018) Haleh Ashraf et al. CYTOKINE
- Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities
- (2018) Sang-Bing Ong et al. PHARMACOLOGY & THERAPEUTICS
- Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway
- (2017) Lina Sun et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Associations of Apelin, Visfatin, and Urinary 8-Isoprostane With Severe Hypertension in African Americans: The MH-GRID Study
- (2016) Steven R. Horbal et al. AMERICAN JOURNAL OF HYPERTENSION
- Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment
- (2016) Julius Kieswich et al. DIABETOLOGIA
- Visfatin Destabilizes Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice
- (2016) Bo Li et al. PLoS One
- Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
- (2016) Konstantinos Dean Boudoulas et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages
- (2015) Bente Halvorsen et al. ATHEROSCLEROSIS
- Relationship between serum visfatin levels and coronary slow-flow phenomenon
- (2015) Huseyin Altug Cakmak et al. HERZ
- Nicotinamide Phosphoribosyltransferase/Pre–B-Cell Colony Enhancing Factor/Visfatin Plasma Levels and Clinical Outcome in Patients With Dilated Cardiomyopathy
- (2015) Peter Bobbert et al. JOURNAL OF CARDIAC FAILURE
- Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure
- (2014) Xiu-Hua Wang et al. Asian Pacific Journal of Tropical Medicine
- Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects
- (2013) Pedro Saddi-Rosa et al. Cardiovascular Diabetology
- The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin Secretion
- (2013) Robert Spinnler et al. PLoS One
- Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology
- (2012) Tuva B. Dahl et al. Annual Review of Nutrition
- Third Universal Definition of Myocardial Infarction
- (2012) Kristian Thygesen et al. CIRCULATION
- Increased Expression of Visfatin in Monocytes and Macrophages in Male Acute Myocardial Infarction Patients
- (2012) Cheng-An Chiu et al. MEDIATORS OF INFLAMMATION
- Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction
- (2011) Li-Fen Lu et al. CYTOKINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now